Lilly restructures commercial organization

Just days after new President and CEO David Ricks took the reins, Eli Lilly and Co. (NYSE: LLY) announced changes to its commercial leadership and organization, including the departure of Alex Azar as president of Lilly US and the consolidation of its emerging markets and European businesses.

The consolidated business will be called Lilly International and will be led by SVP Alfonso Zulueta, who was head of emerging markets. Lilly Diabetes will house the company’s human pharmaceutical commercial operations in the U.S., China, Japan and Canada. Enrique Conterno, will retain his role as SVP and president of Lilly Diabetes while also taking on Azar’s role. ...